Officials Seek Agreement With China to Address Fentanyl Crisis
Home > Health > Weekly Roundups

Officials Seek Agreement With China to Address Fentanyl Crisis

Photo by:   Abby Anaday
Share it!
Paloma Duran By Paloma Duran | Journalist and Industry Analyst - Thu, 05/18/2023 - 10:15

President Andrés Manuel López Obrador is seeking an agreement with China to exchange information on fentanyl. Currently, fentanyl is one of the most dangerous drugs for Mexicans and Americans. Although authorities have stressed that consumption in Mexico is much lower than in the US, there are still indications of an increase in consumption.

Here's your weekly roundup!

Cuban Vaccine Against COVID-19 Can Be Used in Minors

COFEPRIS has approved the use of the Cuban vaccine to prevent COVID-19 in children over 5 years of age. According to authorities, the vaccine has a 91 percent efficacy rate. In December 2022, Mexican authorities began using this vaccine for those over 18 years of age. However, the population was requesting to investigate if it was safe for pediatric ages.

Mexico's Patria Vaccine Will Have Low Vaccination Coverage

Experts highlight that the Mexican COVID-19 vaccine called Patria will only be used as a booster, so 40% of the population will never receive it.  Laurie Ann Ximénez-Fyvie, head of the molecular genetics’ laboratory at UNAM, emphasized that although the vaccine has proven to be effective, it will only be used by older adults. She also stressed that there is no possibility of children under five years of age receiving the dose. 

Johnson and Johnson's COVID-19 Vaccines Are No Longer Available in the US

The CDC approved the destruction of all remaining Johnson & Johnson's COVID-19 vaccines that had not yet been administered since they reached their expiration date on May 7. As a result, Johnson & Johnson's COVID-19 vaccines are no longer available in the US. The center also advised getting a booster vaccination if the person had received a Johnson & Johnson vaccine. 





 

Photo by:   Abby Anaday

You May Like

Most popular

Newsletter